title: Testing the right target and right drug at the right stage.
abstract: Alzheimer's disease (AD) is the only leading cause of death for which no disease-modifying therapy is currently available. Recent disappointing trial results at the dementia stage of AD have raised multiple questions about our current approaches to the development of disease-modifying agents. Converging evidence suggests that the pathophysiological process of AD begins many years before the onset of dementia. So why do we keep testing drugs aimed at the initial stages of the disease process in patients at the end-stage of the illness?
authors: Center for Alzheimer Research and Treatment, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02446, USA. reisa@rics.bwh.harvard.edu
authors: Reisa A
authors: RA
authors: Sperling
authors: Clifford R
authors: CR
authors: Jack
authors: Paul S
authors: PS
authors: Aisen
mesh_terms: D000544:Alzheimer Disease / Q000188:drug therapy* / Q000473:pathology*; D002986:Clinical Trials as Topic; D006801:Humans; D058990:Molecular Targeted Therapy